Request Demo

Last update 01 Jun 2025

Fentanyl

Last update 01 Jun 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryFentanyl is a synthetic opioid that is highly effective in the management of severe pain, especially in cancer patients. It exerts its analgesic effects by binding to opioid receptors in the central nervous system. Fentanyl is available in various formulations, including transdermal patches, lozenges, and injectable solutions. However, due to its potency, fentanyl carries a high risk of addiction, respiratory depression, and overdose. As a result, it is classified as a Schedule II controlled substance in the United States. Ongoing research is focused on developing safer and more effective delivery methods for fentanyl, such as abuse-deterrent formulations and novel routes of administration.

Drug Type

Small molecule drug

Synonyms

AeroLEF, Fentany Transdermal System, Fentanyl (JAN/USP/INN)

+ [38]

Target

Opioid receptors

Action

agonists

Mechanism

Opioid receptors agonists(Opioid receptors agonists)

Therapeutic Areas

Nervous System DiseasesOther DiseasesNeoplasms

Active Indication

Cancer PainChronic PainPain+ [3]

Inactive Indication

Acute PainAdvanced cancerBreakthrough Pain+ [11]

Originator Organization

Janssen Global Services LLC

Active Organization

Lee's Pharmaceutical Holdings Ltd.

Medrx Co., Ltd.

Zhaoke Pharmaceutical (Guangzhou) Ltd.

+ [6]

Inactive Organization

Janssen Pharmaceuticals, Inc.

ALZA Corp.Janssen Research & Development LLC

+ [4]

License Organization

Terumo Corp. /Hemodialyzer Marketing Operations/

Nutriband, Inc.

Kindeva Drug Delivery LP

+ [4]

Drug Highest PhaseApproved

First Approval Date

United States (07 Aug 1990),

HypoventilationPain, Postoperative

Regulation-

Structure/Sequence

Molecular FormulaC22H28N2O

InChIKeyPJMPHNIQZUBGLI-UHFFFAOYSA-N

CAS Registry437-38-7

810

Clinical Trials associated with Fentanyl

NCT06953453

/ Not yet recruitingPhase 1

A Phase I Clinical Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With Malignant Tumors

This study is a single-dose, open-label, 2-cycle crossover design, comparing the pharmacokinetic parameters and safety of Inhaled Fentanyl Aerosol and intravenous fentanyl injection.

Start Date20 Dec 2025

Sponsor / Collaborator

Lee's Pharmaceutical Holdings Ltd.

NCT06696586

/ Not yet recruitingPhase 4IIT

Comparison Between Effect of Systemic Fentanyl Infusion and Fentanyl Added as An Adjuvant to Lidocaine in Bier Block For Controlling Pain in Patients Undergoing Hand Surgeries

Injury and deformity of the upper extremity can result in dysfunction to nerves, tendons and bones which can lead to disability and pain.
Various techniques of regional anesthesia are frequently used for upper extremity surgery. Specifically, intravenous regional anesthesia, the Bier block, is an effective anesthetic technique. This technique, developed by Dr August Bier in 1908, provides complete anesthesia, a bloodless field, and eliminates the need for general anesthesia. However, it was not until the 1960s that this technique was reintroduced and used in upper extremity surgery due to several disadvantages and reports of major complications. Because of the dose of lidocaine and tourniquet time, there is potential for cardiac and neurological complications such as arrhythmias, seizures, and compartment syndrome the aim of this study To evaluate the effect of Systemic Fentanyl Infusion compared to addition of Fentanyl as An Adjuvant to Lidocaine in Bier Block for Controlling Pain in Patients Undergoing Hand Surgeries

Start Date01 Jul 2025

Sponsor / Collaborator

Assiut University

NCT06962306

/ RecruitingPhase 4IIT

Perioperative Methadone Use for Cleft Palate Repair: A Randomized Controlled Trial

The purpose of this study is to compare the use of short acting opioids (fentanyl/hydromorphone) with long acting opioids (methadone) for pain control following cleft palate surgery in infants and young children.

Start Date15 Jun 2025

Sponsor / Collaborator

Duke University

100 Clinical Results associated with Fentanyl

100 Translational Medicine associated with Fentanyl

100 Patents (Medical) associated with Fentanyl

29,996

Literatures (Medical) associated with Fentanyl

31 Dec 2025·ANNALS OF MEDICINE

Respiratory depression in women receiving propofol/esketamine versus propofol/fentanyl for abortion surgery or curettage: a randomized clinical trial

Article

Author: Chen, Huihe ; Guan, Xuehai ; Luo, Jiaxin ; Wu, Xiaoshan ; Cao, Huiyu ; Lan, Hongmeng ; Lin, Yuliu ; Zhang, Cuiwen ; Liao, Yeqing ; Huang, Xiaofang

BACKGROUND:

A combination of opioids with propofol is a popular approach to non-intubated general anaesthesia; however, this method usually results in higher incidence of respiratory depression. We compared the incidence of esketamine- and fentanyl-induced respiratory depression in women undergoing abortion surgery or curettage under propofol-based non-intubated general anaesthesia.

METHODS:

This study included 176 women (aged 18-60 years) scheduled for abortion surgery or curettage. Patients were randomized into the fentanyl or esketamine groups. Patients in the fentanyl group received fentanyl (1 µg/kg) combined with propofol intravenously. Patients in the esketamine group received subanaesthetic doses of esketamine (0.15 mg/kg) combined with propofol intravenously. The primary outcome was the incidence of respiratory depression during anaesthesia. Secondary outcomes included respiratory rate, pulse oximetry, blood pressure, heart rate, propofol dose, duration of surgery, duration of anaesthesia, and adverse events.

RESULTS:

The incidence of respiratory depression in the esketamine group was significantly lower than that in the fentanyl group (11% vs. 45%; p < .0001). Propofol administration was lower with esketamine than fentanyl. Respiratory rate, SpO₂ and blood pressure were more stable in the esketamine group than in the fentanyl group. The incidences of hypotension, propofol-induced injection pain and chin lifting in the esketamine group were lower than those in the fentanyl group. The incidence of nightmares was higher in the esketamine than in the fentanyl group.

CONCLUSIONS:

The incidence of respiratory depression was lower with subanaesthetic doses of esketamine than with fentanyl in women undergoing abortion surgery or curettage under propofol-based non-intubated general anaesthesia.KEY MESSAGESOpioids combined with propofol is a popular method for non-intubated general anaesthesia; however, this method usually results in higher incidence of respiratory depression.At subanaesthetic doses, esketamine provides an analgesic effect by antagonizing the N-methyl-d-aspartate receptor.In this trial, the incidence of respiratory depression was lower with subanaesthetic doses of esketamine than with fentanyl in women undergoing abortion surgery or curettage under propofol-based non-intubated general anaesthesia.

01 Nov 2025·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

A novel label-free carbon dots-based fluorescent aptamer sensor for the detection of fentanyl

Article

Author: Tong, Yishuo ; Yan, Jiangwei ; Niu, Weifen ; Wang, Zheyu ; Liu, Baihui ; Dong, Chuan

Fentanyl, a widely abused potent synthetic opioid, poses a challenge due to its narrow therapeutic window, increasing the risk of overdose and death. Fast, easy, and cost-effective screening for fentanyl in biological samples is crucial for forensic and public safety purposes. We hereby present a label-free fluorescence sensor for the precise and sensitive identification of fentanyl, utilizing carbon dots (CDs) in conjunction with aptamers. By synthesizing green-emitting CDs in a single step using an environmentally friendly method with o-phenylenediamine (OPD) and thiourea in acetone, the CDs displayed excellent optical properties and biocompatibility. Due to the positive charge of CDs, their fluorescence quenching is caused by electrostatic interactions with negatively charged aptamers. When fentanyl is introduced, the specific binding between fentanyl and the fentanyl aptamer is strengthened, resulting in fluorescence recovery. Under optimal experimental conditions, there was a linear relationship between fluorescence intensity and fentanyl concentration in the 5-1000 nM with a limit of determination of 1.90 nM. The robust quantification of fentanyl in complex human saliva matrices achieved by this aptamer-based biosensing platform validates its clinical reliability, particularly for non-invasive point-of-care monitoring and harm-reduction interventions in opioid crisis management.

01 Sep 2025·TALANTA

SERS detection of analgesics in serum based on Ag nanocubes for perioperative monitoring

Article

Author: Qin, Lei ; Ji, Yinghe ; Han, Lin ; Wu, Jing ; Wang, Yunpeng ; Zhu, Zhuo ; Li, Yang ; Sun, Tingting

Prompt and personalized perioperative analgesia management relies on sensitive and convenient monitoring of analgesics. We report a strategy for sensitive and reproducible SERS detection of analgesics based on Ag nanocubes, which have abundant intragranular hot spots on sharp corners and interparticle hot spots between gaps. Both theoretical simulations and R6G detection experiments indicated that the enhancement factor of Ag nanocube SERS platform reach to 10⁶ level. Quantitative and reproducible determination capabilities of this platform for six different analgesics with LOD as low as 500 pg mL^-1 were verified. Pharmacokinetic experiment of fentanyl in rat serum samples by SERS detection within 4 h presented consistent results with the UHPLC-MS/MS method. Valid examples of SERS detection for single or multiple analgesics in clinical patients' serums further proved the feasibility of this platform for perioperative analgesic monitoring.

387

News (Medical) associated with Fentanyl

01 May 2025

·www.prnewswire.com

New Study Highlights Monthly SUBLOCADE® as a Potential Treatment Option for Opioid Use Disorder During and After Pregnancy

SUBLOCADE use during pregnancy showed no increased risk of birth defects, miscarriage, or maternal complications compared to general population rates RICHMOND, Va., May 1, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced the publication of a study "Monthly Buprenorphine Depot Injection (SUBLOCADE) for Opioid Use Disorder During Pregnancy" in the American Journal on Addictions, evaluating the use of SUBLOCADE for the treatment of opioid use disorder (OUD) during pregnancy and postpartum. Three sources of data evaluated in this retrospective study illustrated that the use of monthly SUBLOCADE during pregnancy demonstrated no increased risk and is consistent with the established buprenorphine safety profile.1 This retrospective study includes clinical case studies from four pregnant patients treated with monthly SUBLOCADE, postmarketing surveillance data covering more than five years, and a targeted literature review. In total, 322 reports of pregnancy exposures to SUBLOCADE were identified. Of the four patients included in the clinical practice case studies, all delivered full-term infants with normal birthweight, no fetal anomalies, and no need for treatment for neonatal opioid withdrawal syndrome (NOWS). "The findings shared in this manuscript support perinatal, patient-centered decision-making," said Melinda Ramage, FNP-BC, CARN-AP, LCAS, Director of the North Carolina Perinatal Substance Use Disorder Network and lead author of the publication. "Treatment is not one-size-fits-all, and it is important to explore safe and effective options for the mother–baby dyad." Between 2010 and 2017, opioid use during pregnancy dramatically increased, with a 131% increase in opioid use-related diagnoses at delivery in the U.S.2 The U.S. national maternal morbidity and mortality data reveal mental health and substance use disorders are the leading underlying cause of pregnancy-related deaths in 36 states. While pregnancy-associated overdose deaths have been steadily rising since 2007, those involving fentanyl and other synthetic opioids markedly increased from 5.73 to 9.47 deaths per 100,000 in a span of just 3 years (2017–2020), with most deaths occurring post-delivery.3 This study helps address the current knowledge gap with relevant experience from patients and prescribers who used monthly SUBLOCADE during pregnancy and/or postpartum. In addition to the case studies, the postmarketing surveillance data showed live births with no reported birth defects in the majority of known cases and rates of spontaneous abortion and other outcomes consistent with or lower than general population rates. Review of relevant literature also aligned with the findings from postmarketing and clinical data sources. These data highlight buprenorphine's established safety profile and offers practical insights into clinical care. "OUD patients who are pregnant run the risk of experiencing a number of negative health consequences, such as infection, overdose, severe maternal morbidity, postpartum readmission, and even death, and using opioids during pregnancy has been linked to poor results for both the fetus and the newborn," said Christian Heidbreder, Chief Scientific Officer at Indivior. "As public health professionals and policymakers look for ways to reduce maternal overdose deaths, this study offers important new information about how long-acting medications like SUBLOCADE might be incorporated into a broader strategy to increase access and enhance outcomes for families affected by OUD." Treatment decisions during pregnancy and postpartum should reflect a shared decision-making approach between providers and patients, aligning with clinical guidance and product labeling. The patient-centered model is especially critical when managing chronic conditions, like OUD, in the perinatal period. These data support consideration of using SUBLOCADE as part of evidence-based treatment options, which include offering or continuing perinatal medications for OUD, prioritizing patient stability when considering a change of existing pharmacotherapy in pregnancy and postpartum, and assessing the benefits and risks in a patient-centered framework. This is the largest amount of data available regarding the experience of pregnant patients on SUBLOCADE. Limitations of the study include limited descriptive data for case studies obtained from a small patient cohort and 21% of pregnancies reported outcomes for postmarketing surveillance. Disclosure: This work was funded by Indivior Inc., with the exception of the case studies and the time and contributions of Melinda Ramage, which were not supported by Indivior. About SUBLOCADE® SUBLOCADE ® (buprenorphine extended-release) injection, for subcutaneous use, CIII INDICATION AND HIGHLIGHTED SAFETY INFORMATION INDICATION SUBLOCADE is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine. SUBLOCADE should be used as part of a complete treatment plan that includes counseling and psychosocial support. HIGHLIGHTED SAFETY INFORMATION WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; SUBLOCADE RISK EVALUATION AND MITIGATION STRATEGY Serious harm or death could result if administered intravenously. SUBLOCADE forms a solid mass upon contact with body fluids and may cause occlusion, local tissue damage, and thrombo-embolic events, including life-threatening pulmonary emboli, if administered intravenously. Because of the risk of serious harm or death that could result from intravenous self-administration, SUBLOCADE is only available through a restricted program call the SUBLOCADE REMS Program. Healthcare settings and pharmacies that order and dispense SUBLOCADE must be certified in this program and comply with the REMS requirements. CONTRAINDICATIONS Hypersensitivity to buprenorphine or any other ingredients in SUBLOCADE. WARNINGS AND PRECAUTIONS Addiction, Abuse, and Misuse: SUBLOCADE contains buprenorphine, a Schedule III controlled substance that can be abused in a manner similar to other opioids. Monitor patients for conditions indicative of diversion or progression of opioid dependence and addictive behaviors. Respiratory Depression: Life threatening respiratory depression and death have occurred in association with buprenorphine. Warn patients of the potential danger of self-administration of benzodiazepines or other CNS depressants while under treatment with SUBLOCADE. Risk of Serious Injection Site Reactions: Likelihood of may increase with inadvertent intramuscular or intradermal administration. Evaluate and treat as appropriate. The most common injection site reactions are pain, erythema and pruritus with some involving abscess, ulceration and necrosis. Neonatal Opioid Withdrawal Syndrome: Neonatal opioid withdrawal syndrome (NOWS) is an expected and treatable outcome of prolonged use of opioids during pregnancy. Adrenal Insufficiency: If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid. Risk of Opioid Withdrawal with Abrupt Discontinuation: If treatment with SUBLOCADE is discontinued, monitor patients for several months for withdrawal and treat appropriately. Risk of Hepatitis, Hepatic Events: Monitor liver function tests prior to and during treatment. Risk of Withdrawal in Patients Dependent on Full Agonist Opioids: Verify that patients have tolerated transmucosal buprenorphine before injecting SUBLOCADE. Treatment of Emergent Acute Pain: Treat pain with a non-opioid analgesic whenever possible. If opioid therapy is required, monitor patients closely because higher doses may be required for analgesic effect. ADVERSE REACTIONS Adverse reactions commonly associated with SUBLOCADE (in ≥5% of subjects) were constipation, headache, nausea, injection site pruritus, vomiting, increased hepatic enzymes, fatigue, and injection site pain. For more information about SUBLOCADE, the full Prescribing information including BOXED WARNING, and Medication Guide, visit . About Opioid Use Disorder (OUD) Opioid Use Disorder (OUD) is a chronic disease in which people develop a pattern of using opioids that can lead to negative consequences. OUD may affect the parts of the brain that are necessary for life-sustaining functions. About Indivior Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat opioid use disorder (OUD). Our vision is that all patients around the world will have access to evidence-based treatment for OUD and we are dedicated to transforming OUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit to learn more. Connect with Indivior on LinkedIn by visiting . References: Ramage M, Bishop B, Mangano V, Mankabady B. Monthly Buprenorphine Depot Injection (SUBLOCADE®) for Opioid Use Disorder During Pregnancy. Am J Addict. 2025. Hirai AH, Ko JY, Owens PL, Stocks C, Patrick SW. Neonatal abstinence syndrome and maternal opioid-related diagnoses in the US, 2010–2017. JAMA. 2021; 325(2): 146-155. doi:10.1001/jama.2020.24991 Bruzelius E, Martins SS. US trends in drug overdose mortality among pregnant and postpartum persons, 2017–2020. JAMA. 2022; 328(21): 2159-2161. doi:10.1001/jama.2022.17045 SOURCE Indivior PLC WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultClinical Study

29 Apr 2025

·www.fiercepharma.com

Indivior-backed paper champions fast-acting overdose reversal meds against synthetic opioids

Indivior is the maker of several treatments for opioid use disorder, as well as Opvee, which in May 2023 earned the first FDA approval for a nasal spray version of active ingredient nalmefene. A paper published this month in the journal Current Addiction Reports discusses the merits of intranasal medications that can reverse overdoses of high-potency synthetic opioids (HPSOs) such as fentanyl.Indivior funded the manuscript, which was based on the results of last summer’s Reversing Synthetic Opioid Overdose (RESPIRE) Expert Forum—also funded by the addiction-focused pharma—that brought together eight leaders representing emergency medicine, pharmacy, state health agencies, Indian Health Services, addiction research and forensic science.The company makes Opvee, an opioid overdose reversal medication that aligns with the expert panel’s recommendations.“Indivior is committed to partnering closely with healthcare providers, policymakers, and communities to ensure that advanced overdose reversal solutions reach those who need them most, especially as HPSOs drive unprecedented risks and challenges,” Christian Heidbreder, Ph.D., the company’s chief scientific officer, said in a statement.The paper’s publication came shortly before National Fentanyl Awareness Day, observed every year on April 29. Fentanyl and other synthetic opioids were involved in more than 90% of opioid overdose fatalities in the year preceding the July forum, according to the report. Indivior is the maker of several treatments for opioid use disorder, as well as Opvee, which in May 2023 earned the first FDA approval for a nasal spray version of active ingredient nalmefene.Naloxone is the current standard of care for treating opioid overdoses and is more widely available than nalmefene—helped along by its first over-the-counter FDA approval for Emergent BioSolutions’ 4 mg Narcan in early 2023. The new paper’s authors, however, suggest that nalmefene may be more effective in treating some overdoses, especially those involving HPSOs.The most crucial aspects of medications used to treat overdoses of synthetic opioids are rapid onset, long duration and high potency, according to the authors.Nalmefene outpaces naloxone on all three of those aspects: Data cited in the paper show that nalmefene has a higher opioid receptor affinity than naloxone. And, while naloxone reaches peak blood concentration in 30 minutes and has a circulating half-life of about two hours, nalmefene’s time to peak is 15 minutes and its half-life is longer than 11 hours, which may make it “particularly well-suited for reversing HPSO overdose,” they wrote.The experts also pointed to a model predicting that a single 4 mg dose of naloxone would reduce the likelihood of cardiac arrest following a fentanyl overdose from about 78% to 47%, while a single 3-mg dose of nalmefene would bring it down to 11.6%. Previous expert publications, including a September 2023 joint release (PDF) from the American College of Medical Toxicology and the American Academy of Clinical Toxicology, have suggested that more research is needed into the risks and benefits of nalmefene, as its longer duration of action could potentially lead to a longer period of the opioid withdrawal symptoms that are the primary adverse effect of all reversal meds.That longer duration may also create a “false sense of comfort that no further care is needed,” possibly leading patients to avoid seeking follow-up observation, the groups wrote at the time, concluding that nalmefene shouldn’t yet replace naloxone as the standard of care for opioid overdose reversal.Though the RESPIRE experts acknowledged the increased risk of precipitated withdrawal following overdose reversal with nalmefene, they wrote that such risks are “secondary to saving a life.”“With the ability to medically manage precipitated withdrawal, in concert with the uncertainty and unpredictability of HPSOs, overdose reversal strategies and agents that rapidly restore and sustain respiration should be aggressively implemented,” they wrote.The panel concluded by calling for greater research and real-world evidence collection around treatments for HPSO overdoses. And, to boost treatment with both naloxone and nalmefene, they “emphatically” recommended improvements to bystander education and training, greater access to reversal agents and a wide-scale destigmatization of addiction.“Only with investments in using new reversal medications, further controlled trials yielding strong evidence, adequately training bystanders and first responders, collecting outcome information, researching and developing new reversal agents, and improving access to opioid use disorder treatment and prevention will the opioid overdose epidemic be marshaled to avoid needless deaths,” they wrote.

Drug Approval

26 Apr 2025

·www.echemi.com

100,000 Lives Lost Annually! Chinese Prison Tied to U.S. Fentanyl Crisis

A recent investigation has uncovered a disturbing link between a Chinese prison and the U.S. fentanyl epidemic, which claims approximately 100,000 American lives each year. This revelation has intensified scrutiny on China’s role in the opioid crisis and raised questions about international efforts to curb the flow of this deadly drug. In a landmark case, nine individuals were convicted in China for smuggling fentanyl into the United States. This joint operation between Chinese and American authorities marked a significant step in cross-border narcotics enforcement. However, despite these efforts, the synthetic opioid continues to flood U.S. streets, often through complex supply chains involving Chinese chemical manufacturers and Mexican cartels. The U.S. has imposed tariffs and sanctions in an attempt to pressure China into stricter regulation of fentanyl precursors. While China has taken steps to control these substances, including classifying all fentanyl-related compounds as controlled drugs in 2019, the effectiveness of these measures remains under scrutiny. Critics argue that the root of the crisis lies within the United States, pointing to overprescription of opioids and inadequate addiction treatment resources. Nonetheless, the international dimension of fentanyl production and distribution cannot be ignored. As the death toll rises, the urgency for comprehensive strategies involving both domestic policy reform and international cooperation becomes increasingly clear. The recent convictions in China may signal a willingness to collaborate, but sustained efforts are essential to stem the tide of this devastating epidemic.

Biosimilar

100 Deals associated with Fentanyl

External Link

KEGG	Wiki	ATC	Drug Bank
D00320	Fentanyl	N02AB03 N01AH01	DB00813

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Cancer Pain	Japan	Janssen Pharmaceutical KK	01 Feb 2011
Pain	Australia	Janssen-Cilag Pty Ltd.	23 Nov 2005
Acute Pain	United States	Janssen Pharmaceuticals, Inc.	04 Feb 2005
Chronic Pain	United States	Janssen Pharmaceuticals, Inc.	04 Feb 2005
Hypoventilation	United States	Janssen Pharmaceuticals, Inc.	07 Aug 1990
Pain, Postoperative	United States	Janssen Pharmaceuticals, Inc.	07 Aug 1990

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Mucositis	Phase 3	United States	INSYS Therapeutics, Inc.	01 Oct 2009
Solid tumor	Phase 3	United States	INSYS Therapeutics, Inc.	01 Oct 2009
Stomatitis	Phase 3	United States	INSYS Therapeutics, Inc.	01 Oct 2009
Low Back Pain	Phase 3	Japan	Janssen Pharmaceuticals, Inc.	01 Jan 2009
Osteoarthritis	Phase 3	Japan	Janssen Pharmaceuticals, Inc.	01 Jan 2009
Complex Regional Pain Syndromes	Phase 3	Japan	Janssen Pharmaceuticals, Inc.	01 Dec 2008
Neuralgia, Postherpetic	Phase 3	Japan	Janssen Pharmaceuticals, Inc.	01 Dec 2008
Pain Disorder	Phase 3	Japan	Janssen Pharmaceuticals, Inc.	01 Dec 2008
Neoplasms	Phase 3	Canada	INSYS Therapeutics, Inc.	01 Dec 2007
Neoplasms	Phase 3	India	INSYS Therapeutics, Inc.	01 Dec 2007

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASH2024	Not Applicable	Acute Pain \| Anemia, Sickle Cell	-	Intranasal Fentanyl (INF)	lfcjspdvfe(sabflmloxf) = 7 (18%) of visits zzmgvtoort (ojjzgxmqeo ) View more	-	08 Dec 2024
NCT05244226 (CTgov)	Phase 2	Sleep Apnea, Obstructive \| Tonsillitis \| Pain, Procedural	66	Hydromorphone+Fentanyl	rkaojeozld(baensbubqd) = iohkdjeham vuzlhigzjw (psrtkyrskb, kxirolshhm - nbucpgbexg) View more	-	17 Oct 2024
NCT03872700 (CTgov)	Phase 3	Abscess	49	Intranasal fentanyl (Intranasal Fentanyl)	txaetnnpfq(ajxffelyjy) = hbzbcnijro arrxnchorx (garxwclqzd, 1.5) View more	-	15 Aug 2023
				Placebo (Placebo)	txaetnnpfq(ajxffelyjy) = vrpwqrfxgc arrxnchorx (garxwclqzd, 2.9) View more
ICML2023	Not Applicable	18 FDG	-	Fentanyl pre-treatment	vlavtwrmms(lbydepnrwm) = fuzhxnjmgs edsrfrlkkv (emkwfdrrxq )	Positive	09 Jun 2023
				No fentanyl pre-treatment	vlavtwrmms(lbydepnrwm) = awubophtrc edsrfrlkkv (emkwfdrrxq )
P12-11.015 (AAN2023)	Not Applicable	Parkinson Disease	1,581	Fentanyl patch	pobpfvuzcd(hcucrfsyya) = involuntary, nonsuppressible writhing motion of the face, trunk and all limbs dsrgbozcoa (wvjmirmgxv ) View more	Negative	25 Apr 2023
Pubmed \| Braz J Anesthesiol	Not Applicable	Anesthesia	-	Spinal fentanyl	cichodeqgz(cyswckrqan) = nxnvgkkemt dikezcugir (ozheksrdvz )	-	01 Mar 2023
				Spinal sufentanil	cichodeqgz(cyswckrqan) = davjcolwup dikezcugir (ozheksrdvz )
NCT00580489 (CTgov)	Not Applicable	Pain \| Drug-Related Side Effects and Adverse Reactions	204	fentanyl+morphine (Arm C Morphine)	bsjjyzuvph = fpqaajfvlx ujnyhfobnn (spffrjthbl, ytiqqsijxl - ednenmddhq)	-	16 Aug 2022
				fentanyl+morphine (Arm D Fentanyl)	bsjjyzuvph = cipdczpiub ujnyhfobnn (spffrjthbl, gppgykobjx - zyhwlabxse)
NCT03776838 (NOLGYN, Pubmed \| Anaesth Crit Care Pain Med)	Phase 4	-	70	NOL-guided administration of fentanyl	qfdtmpaulu(meydnjyfkj) = jqrsiyrmtj jgshhawofv (qhnbbeqajq, 99.9 - 113.4)	Positive	25 May 2022
				intravenous fentanyl (Standardized care)	qfdtmpaulu(meydnjyfkj) = whjcmckymg jgshhawofv (qhnbbeqajq, 97.5 - 110.7)
NCT03792191 (CTgov)	Not Applicable	Anesthesia \| Obesity	280	Lumbar Spinal Ultrasonography+Intrathecal Fentanyl+Intrathecal Bupivacaine (Ultrasonography)	fkhrxqwgap(drwsthatux) = rhuugafewp kwerrefznx (fdspmwyfdv, gurauiskry - wetxrvzukf) View more	-	24 May 2021
				Conventional Landmark Palpation+Intrathecal Fentanyl+Intrathecal Bupivacaine (Palpation)	fkhrxqwgap(drwsthatux) = vftsoppthx kwerrefznx (fdspmwyfdv, htfffyrwnm - ebovxspptt) View more
NCT02514252 (CTgov)	Phase 2	Breakthrough Pain \| Advanced cancer	6	Study Diary+Fentanyl	tpafgljnpg(ipteeyhptq) = tknebfzkkn xnoqrffysr (vojmpxwraf, qegbqzgtqu - jhrtocrquq) View more	-	18 May 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis